A Single Dose, Randomized, Three-Period, Three-Treatment, Crossover Bioequivalency Study of Cilostazol 100 mg Tablets Under Fasting Conditions

Roxane Laboratories1 个研究点分布在 1 个国家目标入组 32 人开始时间: 2003年5月1日最近更新: 2018年1月23日

适应症

试验速览

阶段: 不适用
状态: 已完成
发起方: Roxane Laboratories
入组人数: 32
试验地点: 1
主要终点: Bioequivalence

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The objective of this study was the bioequivalence of a Roxane Laboratories' Cilostazol Tablets, 100 mg, to PLETAL® Tablets, 100 mg (OTSUKA Pharmaceuticals) under fasting conditions using a single-dose, randomized, 3-treatment, 3-period, crossover design.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Crossover
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 45 Years（Adult）
性别: All
接受健康志愿者: 是

入选标准

•No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening.

排除标准

•Positive test for HIV, Hepatitis B, or Hepatitis C.
•Treatment with known enzyme altering drugs.
•History of allergic or adverse response to Cilostazol or any comparable or similar product.

结局指标

主要结局

Bioequivalence

时间窗: Baseline, Two period, Seven day washout

次要结局

未报告次要终点

研究者

发起方

Roxane Laboratories

申办方类型

Industry

研究点 (1)

Loading locations...

相似试验

已完成

不适用

Bioequivalency Study of 50 mg Cilostazol Tablets Under Fasting ConditionsIntermittent Claudication

NCT00602407Roxane Laboratories36

已完成

不适用

Bioequivalency Study of Anastrozole 1 mg Under Fed ConditionsBreast Cancer

NCT01155089Roxane Laboratories32

已完成

1 期

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed ParticipantsHealthy

NCT02071368Janssen Research & Development, LLC3

已完成

1 期

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed ParticipantsHealthy

NCT02077803Janssen Research & Development, LLC47

已完成

1 期

Bioequivalence Study of Abiraterone Acetate Coated and Uncoated Tablet Formulations in Healthy Male ParticipantsHealthy

NCT02230046Janssen Research & Development, LLC102